For Research Use Only. Ipamorelin is intended exclusively for laboratory research. It is not approved for human or veterinary use and should never be administered to humans or animals outside of a controlled research setting.
What Is Ipamorelin and How Does It Engage the Ghrelin Receptor?
Ipamorelin is a five-amino-acid peptide built around the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2, designed in research labs as a selective ligand for GHS-R1a. The receptor itself is a G-protein coupled receptor expressed prominently in the anterior pituitary and the hypothalamic arcuate nucleus, where it integrates signals that regulate growth hormone pulsatility. The native ligand for GHS-R1a is octanoylated ghrelin, a 28-amino-acid peptide released from the stomach. Ipamorelin mimics the receptor-binding face of ghrelin closely enough to act as a full agonist at GHS-R1a, while sparing other receptors that octanoylated ghrelin can engage at higher concentrations. The structure of GHS-R1a and its ligand-binding pocket is reviewed across literature collected on the ScienceDirect ghrelin receptor topic page.
How Does GHS-R1a Activation Drive Growth Hormone Release in Research?
When ipamorelin binds GHS-R1a on a somatotroph cell surface, the receptor couples to the Gq/11 protein family and activates phospholipase C beta. Inositol trisphosphate then triggers calcium release from intracellular stores, and the rise in cytosolic calcium drives growth hormone secretory granule exocytosis. In rodent and pig models, this signal results in a clean GH pulse measurable within minutes of administration, with peak amplitude depending on quantity, route, and the animal's prior nutritional state. Research using somatotroph cell lines and primary pituitary cultures has mapped the calcium-dependent secretion in detail, and the broader literature on GH pulse kinetics is published heavily in Frontiers in Endocrinology. Our CJC-1295 with DAC vs no-DAC half-life comparison explores how GHRH analogs interact with the same somatotroph machinery.
Why Does Ipamorelin Show Minimal Cortisol and Prolactin Response?
Earlier growth hormone secretagogues like GHRP-6 and hexarelin reliably stimulate measurable cortisol and prolactin release in research animals, an off-target signature that confounds interpretation of GH-axis studies. Ipamorelin's structural design narrows its receptor engagement, producing minimal cortisol and prolactin elevation in matched preclinical assays. The likely explanation is that the lactotroph and corticotroph cell populations express different secretagogue receptor subtypes and downstream signaling architecture, so a ligand built for selectivity at the somatotroph GHS-R1a does not efficiently trigger the others. Comparative pharmacology data on this selectivity is published across Cell Metabolism and the Wiley Online Library endocrinology collection. Researchers studying isolated GH-pathway effects in animal models often choose ipamorelin precisely for this clean readout.
What Preclinical Models Use Ipamorelin to Study GHS-R1a Signaling?
Ipamorelin appears in three categories of preclinical research. First, isolated cell systems including pituitary cell lines and primary somatotrophs use ipamorelin to characterize receptor binding, calcium dynamics, and acute GH release. Second, rodent in-vivo studies measure plasma GH pulse amplitude, IGF-1 downstream response, and tissue-level effects after ipamorelin administration; the IGF-1 axis is reviewed in our CJC-Ipa IGF-1 axis research overview. Third, large-animal models including pigs and dogs have been used to characterize secretagogue pharmacology because the somatotroph GH-pulse architecture in those species is closer to humans than rodent models. Across all three categories, the consistent ipamorelin signature is a measurable GH pulse with minimal off-target hormone elevation, which supports its use as a research-grade probe for GHS-R1a-specific mechanisms.
How Does Ipamorelin Compare to Other GHS-R1a Agonists in Research?
The GHS-R1a agonist family includes the natural ligand octanoylated ghrelin, peptide secretagogues like GHRP-6, hexarelin, and ipamorelin, and small-molecule agonists such as anamorelin and capromorelin. Ipamorelin's distinguishing characteristics in comparative research include its selectivity profile at GHS-R1a relative to lactotroph and corticotroph receptors, its short plasma half-life appropriate for pulse-kinetics work, and its reliable production at preclinical scale. Anamorelin and capromorelin have longer half-lives and have been used in oral-formulation research for their pharmacology profile, while GHRP-6 remains common in older comparative literature. For studies that combine a secretagogue with a GHRH analog to capture both arms of GH regulation, the cluster post on CJC-1295 / Ipamorelin blend research reviews the typical study design.
What Should Researchers Consider When Sourcing Ipamorelin for GHS-R1a Studies?
Researchers sourcing ipamorelin for GHS-R1a work should require batch-specific Certificates of Analysis showing 99 percent purity by HPLC and identity confirmation by mass spectrometry, along with clear research-use-only labelling. The supplier should disclose lot numbers, the testing laboratory, and recommended storage. Lyophilized ipamorelin is typically stored frozen and reconstituted in bacteriostatic water for short-term refrigerated use within a documented stability window. Midwest Peptide stocks the CJC-1295 / Ipamorelin blend for studies that combine a GHRH analog with a selective GHS-R1a agonist, and our CJC-1295 / Ipamorelin supplier evaluation guide walks through the supplier-evaluation checklist in more detail. Background on peptide identity and synthesis quality control is collected in Frontiers in Pharmacology.
Frequently Asked Questions